Prescriber's Corner

Tazemetostat: EZH2 Inhibitor

Rachael Straining, PharmD, and William Eighmy, PharmD

From Yale New Haven Health Smilow Cancer Hospital, New Haven, Connecticut

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Rachael Straining, PharmD, Smilow Cancer Hospital, 35 Park Street, New Haven, CT 06519. E-mail: rlauren2012@yahoo.com


J Adv Pract Oncol 2022;13(2):158–163 | https://doi.org/10.6004/jadpro.2022.13.2.7 | © 2022 Harborside™


  

ABSTRACT

Epigenetic regulation is a novel approach to cancer treatment. Inhibition of enhancer of zeste homolog 2 (EZH2) is a method to provide targeted epigenetic regulation. Tazemetostat is a first-in-class targeted epigenetic regulator that specifically inhibits EZH2. This new FDA-approved oral treatment received accelerated approval for patients with hematologic and solid malignancies. Tazemetostat was first approved for patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection based on the results of an international open-label phase II basket trial. Another open-label multicenter phase II trial led to the approval for patients with relapsed or refractory follicular lymphoma with EZH2 mutation who have received at least two prior systemic therapies or patients who have no satisfactory alternative treatment options. Tazemetostat as an oral EZH2 inhibitor provides a new effective and tolerable treatment option for these patients.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.